Once again, JP Morgan sets the tone for the year ahead in life sciences.
Beyond discussions on AI, data, and capital allocation, one message stood out across many conversations, especially in smaller, founder- and operator-led settings:
🟥 As technology accelerates, human judgment, trust, and early decision-making are becoming strategic assets.
🟥 AI is increasingly seen as a powerful support for managing complexity and scale, but not a substitute for responsibility, experience, or regulatory and quality foundations.
🟥 The companies best positioned to move fast later are those aligning technical, regulatory, and product thinking much earlier.
📩 We’ve shared an expanded Q&A with our CEO, Andrea Biasiucci, gathering reflections from JP Morgan Healthcare 2026 in our latest newsletter.
Sign up (for free) to read the full conversation.
While you focus on innovation, we take care of the regulatory path!
